Randomized Trial Compares Lactobacillus paracasei LC-19 and Semaglutide for Weight Loss and Metabolic Improvement
Background
Obesity and overweight are global health crises, increasing risks for metabolic disorders. Current interventions often include lifestyle changes, but sustained weight loss and metabolic improvements remain challenging for many. Glucagon-like peptide-1 receptor agonists (GLP-1RA) like semaglutide have shown significant efficacy. However, the role of probiotics in weight management and metabolic health, particularly in direct comparison to established pharmacotherapies, needs further clarification. This trial addresses the comparative efficacy and safety of a specific probiotic strain versus semaglutide.
Study Design
This randomized controlled trial will enroll 120 overweight or obese participants (BMI ≥ 24 kg/m²) and 20 normal-weight controls. Overweight/obese participants are randomized to receive placebo, Lactobacillus paracasei LC-19 (LC-19), or semaglutide for 12 weeks. All participants will also undergo energy-restricted nutritional and lifestyle intervention. Primary endpoints include changes in body weight, energy, glucose, and lipid metabolism, alongside safety and long-term outcomes like weight regain.
Why It Matters
Direct comparison of Lactobacillus paracasei LC-19 and semaglutide for weight management and metabolic health is significant. The findings could inform individualized intervention strategies, offering a potentially gentler, non-pharmacological option for some, or identifying synergistic approaches. Understanding the comparative efficacy and safety profile will be crucial for clinicians and biohackers considering different pathways for obesity and metabolic syndrome management. It may also provide insights into the mechanisms by which probiotics influence energy, glucose, and lipid metabolism, potentially optimizing future protocols for combining or choosing interventions.
lactobacillus paracasei lc-19
semaglutide
obesity
weight loss
probiotic
glp-1 agonist